This study focuses on Geographic Atrophy, a severe form of age-related Macular Degeneration that causes vision loss. This eye condition occurs when certain layers of the retina gradually deteriorate, leading to areas of vision loss in the central field of vision. The study will evaluate a medication called Dimethyl Fumarate, which will be given as oral capsules that are specially coated to protect the stomach.
The purpose of this research is to determine if Dimethyl Fumarate can slow down the growth of areas affected by Geographic Atrophy compared to standard care. The medication will be taken twice daily – starting with a lower dose of 120 mg twice daily for the first week, then increasing to 240 mg twice daily for the remainder of the study period, which lasts about one year.
Throughout the study, participants will have their eyes examined using special imaging techniques called Fundus Auto-fluorescence that allow doctors to measure the affected areas of the retina. The study will also include other eye examinations and safety monitoring. Some participants will undergo MRI scans of the brain before starting treatment to ensure their safety during the study.
France 
